hotspot -WSS

hotspot

author：hotspot 2025-08-26 10:51:50 - browse：184

Photo of an arrangement of aspirin pills — Patrick Sison/AP

Low-dose aspirin led to a reduction in liver fat among patients with metabolic-associated liver disease, a small study out of Boston found.

The clinical trial, led by Tracey Simon of Massachusetts General Hospital and Harvard Medical School, compared two groups of patients with metabolic dysfunction-associated steatotic liver disease, or MASLD. One group was given baby aspirin daily for six months, while the other received a placebo pill. At the end of the study period, the aspirin group had reduced hepatic fat content while the placebo group had higher fat buildup.

MASLD (formerly known as non-alcoholic fatty liver disease) is a growing health threat, with 1 in 3 Americans having a troublesome amount of fat in their liver. The lipid buildup feeds into a toxic cycle of inflammation, tissue damage and, ultimately, irreversible scarring.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： FDA endorses new sterilization method for medical devices

focus

WSS

There's an unseen cost to disruptive road

Ethical issues complicate the benefits of medical crowdfunding

Advances in CAR

Amazon on where the company's health care bets are headed next

Head of FDA's diagnostics center, who led through Covid, retires

NIH nominee Bertagnolli will get October confirmation hearing

hotspot

hotspot

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Snackable artificial intelligence, expert AI, and the pharma industry

State Dept. review finds Biden bears some blame for Afghanistan failures

What causes osteoarthritis? Researchers study link to brain protein

Walensky prepares to leave CDC — and Congress — behind

ALS advocates say criticism of new drugs misses bigger picture

How to save PrEP access — and even expand it

Dog Aging Project founders on what lies ahead after losing funding

Dobbs anniversary: the lost opportunity of abortion as health care

Dog Aging Project founders on what lies ahead after losing funding

entertainment

Maisha Meds is a PBM, but don't call it that

'Make People Better': The CRISPR babies story you probably don't know

AstraZeneca chief proposes a novel edit to the drug pricing bill

Snackable artificial intelligence, expert AI, and the pharma industry

Dog Aging Project founders on what lies ahead after losing funding

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

focus

focus

focus

Wikipedia